Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response

Abstract Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, providing significant benefit to patients across various tumour types, including melanoma. However, around 40% of melanoma patients do not benefit from ICI treatment, and accurately predicting ICI response remains challe...

Full description

Bibliographic Details

Published in:	Molecular Cancer
Main Authors:	Su Yin Lim, Ines Pires da Silva, Nurudeen A. Adegoke, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Jenny H. Lee, Helen Rizos
Format:	Article
Language:	English
Published:	BMC 2024-10-01
Subjects:	Melanoma Immune checkpoint blockade Transcriptomic analysis PD1 CTLA4
Online Access:	https://doi.org/10.1186/s12943-024-02146-0